Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Canada
  4. Bourse de Toronto
  5. Aurora Spine Corporation
  6. News
  7. Summary
    ASG   CA05206X1087

AURORA SPINE CORPORATION

(ASG)
  Report
Delayed Bourse de Toronto  -  12:17 2022-12-02 pm EST
0.4400 CAD   +2.33%
11/21Transcript : Aurora Spine Corporation, Q3 2022 Earnings Call, Nov 21, 2022
CI
11/21Aurora Spine Corporation Announces Third Quarter Fiscal 2022 Financial Results
GL
11/21Aurora Spine Corporation Announces Third Quarter Fiscal 2022 Financial Results
GL
SummaryQuotesChartsNewsCalendarCompanyFinancialsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Aurora Spine Corporation Announces FDA 510(k) Clearance for its SiLO TFX™ MIS Sacroiliac Joint Fixation System

10/04/2022 | 05:54pm EST

CARLSBAD, Calif., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the patented minimally invasive SiLO TFX MIS Sacroiliac Joint Fixation System. Additional details regarding the SiLO TFX MIS Sacroiliac Joint Fixation System will be disclosed by the Company in a more fulsome press release to be issued on October 6, 2022.

About Aurora Spine

Aurora Spine is focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies. Additional information can be accessed at www.aurora-spine.com or www.aurorapaincare.com.

Forward-Looking Statements

This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Information" in Aurora Spine's final prospectus (collectively, "forward-looking information"). Forward-looking information in this news release includes information concerning the proposed use and success of the company’s products in surgical procedures. Aurora Spine cautions investors of Aurora Spine's securities about important factors that could cause Aurora Spine's actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward-looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.

Contact:

Aurora Spine Corporation

Trent Northcutt

President and Chief Executive Officer

(760) 424-2004

Chad Clouse

Chief Financial Officer

(760) 424-2004

www.aurora-spine.com

Adam Lowensteiner

LYTHAM PARTNERS, LLC

Phoenix | New York

Telephone: 646-829-9700

asapf@lythampartners.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Primary Logo


ę GlobeNewswire 2022
All news about AURORA SPINE CORPORATION
11/21Transcript : Aurora Spine Corporation, Q3 2022 Earnings Call, Nov 21, 2022
CI
11/21Aurora Spine Corporation Announces Third Quarter Fiscal 2022 Financial Results
GL
11/21Aurora Spine Corporation Announces Third Quarter Fiscal 2022 Financial Results
GL
11/18Aurora Spine Corporation Reports Earnings Results for the Third Quarter and Nine Months..
CI
11/15Aurora Spine Corporation Schedules Release of Third Quarter Fiscal Year 2022 Financial ..
GL
11/15Aurora Spine Corporation Schedules Release of Third Quarter Fiscal Year 2022 Financial ..
GL
10/28Aurora Spine Corporation Announces Positive Interim Results from Clinical Study using Z..
AQ
10/27Aurora Spine Corp Announced Positive Interim Results from Clinical Study
MT
10/27Aurora Spine Corporation Announces Positive Interim Results from Clinical Study Using Z..
CI
10/27Aurora Spine Corporation Announces Positive Interim Results from Clinical Study using Z..
GL
More news
Financials (USD)
Sales 2021 10,5 M - -
Net income 2021 -2,36 M - -
Net cash 2021 0,63 M - -
P/E ratio 2021 -6,79x
Yield 2021 -
Capitalization 21,8 M 21,8 M -
EV / Sales 2020 2,10x
EV / Sales 2021 1,67x
Nbr of Employees -
Free-Float 81,8%
Chart AURORA SPINE CORPORATION
Duration : Period :
Aurora Spine Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Trent J. Northcutt President, CEO & Non-Independent Director
Chad Clouse Chief Financial Officer
David A. Rosenkrantz Chairman
Laszlo Garamszegi Chief Technology Officer
James Snow Independent Director
Sector and Competitors
1st jan.Capi. (M$)
AURORA SPINE CORPORATION27.54%22
ABBOTT LABORATORIES-23.20%188 463
MEDTRONIC PLC-23.39%105 909
BECTON, DICKINSON AND COMPANY2.06%71 518
DEXCOM, INC.-12.01%45 621
HOYA CORPORATION-18.03%36 935